Furexel Combi

Main information

  • Trade name:
  • Furexel Combi
  • Pharmaceutical form:
  • Oral paste
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Furexel Combi
    United Kingdom
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • ivermectin, combinations
  • Therapeutic area:
  • Horses

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0213/001
  • Authorization date:
  • 28-09-2011
  • EU code:
  • UK/V/0213/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Revised:October2011

AN:01898/2010

Page1of8

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

FurexelCombiOralPaste

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Eachsyringecontains7.74gofpasteanddelivers:

ActiveSubstances:

Ivermectin 0.120g(15.5mg/g)

Praziquantel 0.600g(77.5mg/g)

Excipients:

Buthylhydroxyanisole(E320): 0.002g

SunsetYellow(E110): 0.003g

Ttitaniumdioxide(E171)): 0.155g

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Oralpaste

Smooth,homogeneousorangepaste

4. CLINICALPARTICULARS

4.1Targetspecies

Horses

4.2Indicationsforuse,specifyingthetargetspecies

Forthetreatmentofmixedcestodeandnematodeorarthropodinfestations

inhorses.Thefollowingparasitesofhorsesaresensitivetothe

antiparasiticeffectsoftheproduct:

AdultTapeworms:

Anoplocephalaperfoliata

Anoplocephalamagna

Largestrongyles:

Strongylusvulgaris(adultsandarteriallarvalstages)

Strongylusedentatus(adultsandtissuelarvalstages)

Strongylusequinus(adults)

Triodontophorusspp(adults)

Triodontophorusbrevicauda

Revised:October2011

AN:01898/2010

Page2of8

Triodontophorusserratus

Craterostomumacuticaudatum(adults)

Adultandimmature(intraluminalfourth-stagelarvae)ofsmallstrongylesor

cyathostomes,includingbenzimidazole-resistantstrains:

Coronocyclusspp

Coronocycluscoronatus

Coronocycluslabiatus

Coronocycluslabratus

Cyathostomumspp

Cyathostomumcatinatum

Cyathostomumpateratum

Cylicocyclusspp

Cylicocyclusashworthi

Cylicocycluselongatus

Cylicocyclusinsigne

Cylicocyclusleptostomum

Cylicocyclusnassatus

Cylicodontophorusspp

Cylicodontophorusbicornatus

Cylicostephanusspp

Cylicostephanuscalicatus

Cylicostephanusgoldi

Cylicostephanuslongibursatus

Cylicostephanusminutus

Parapoteriostomumspp

Parapoteriostomummettami

Petrovinemaspp

Petrovinemapoculatum

Poteriostomumspp

Adulthairworms:Trichostrongylusaxei

Adultandimmature(fourthstageLarvae)pinworms:Oxyurisequi

Adult,third-andfourth-stagelarvaeofroundworms(ascarids):

Parascarisequorum

Microfilariaeofneckthreadworms:Onchocercaspp

Adultintestinalthreadworms:Strongyloideswesteri

Adultlarge-mouthstomachworms:Habronemamuscae

Oraland,gastricstagesofbots:Gasterophilusspp

Adultandimmature(inihibitedfourthstagelarvae)lungworms:

Dictyocaulusarnfieldi

4.3Contraindications

Theproducthasbeenformulatedforuseinhorsesonly.Cats,dogs,

especiallycollies,OldEnglishSheepdogsandrelatedbreedsorcrosses.

Alsoturtlesandtortoisesmaybeadverselyaffectedbytheconcentration

ofivermectininthisproductiftheyareallowedtoingestspilledpasteor

haveaccesstousedsyringes.

Revised:October2011

AN:01898/2010

Page3of8

4.4Specialwarningsfortargetspecies

Careshouldbetakentoavoidthefollowingpracticesbecausethey

increasetheriskofdevelopmentofresistanceandcouldultimatelyresult

inineffectivetherapy:

- Toofrequentandrepeateduseofanthelminticsfromthesameclass,

overanextendedperiodoftime.

- Underdosing,whichmaybeduetounderestimationofbodyweight,

misadministrationoftheproduct,orlackofcalibrationofthedosing

device(ifany).

Suspectedclinicalcasesofresistancetoanthelminticsshouldbefurther

investigatedusingappropriatetests(e.g.FaecalEggCountReduction

Test).Wheretheresultsofthetest(s)stronglysuggestresistancetoa

particularanthelmintic,ananthelminticbelongingtoanother

pharmacologicalclassandhavingadifferentmodeofactionshouldbe

used.

Resistancetomacrocycliclactones(whichincludesivermectin)hasbeen

reportedinParascarisequoruminhorsesinanumberofcountries,

includingtheEU.Thereforetheuseofthisproductshouldbebasedon

local(regional,farm)epidemiologicalinformationaboutsusceptibilityof

nematodesandrecommendationsonhowtolimitfurtherselectionfor

resistancetoanthelmintics.

4.5Specialprecautionsforuse

i. Specialprecautionsforuseinanimals

Safetystudieswerenotconductedinfoalsyoungerthan2monthsof

age,orinstallions,theuseoftheproductisnotrecommendedin

thesecategoriesofanimals.

ii.Specialprecautionstobetakenbythepersonadministeringthe

veterinarymedicinalproducttoanimals

Washhandsafteruse.

Donotsmoke,drinkoreatwhilehandlingtheproduct.

Thisproductmaycauseskinandeyeirritation.Therefore,theuser

shouldavoidcontactoftheproductwiththeskinandtheeyes.Inthe

caseofcontact,rinseimmediatelywithplentyofwater.

Inthecaseofaccidentalingestionoreyeirritationaftercontactseek

medicaladviceimmediatelyandshowthepackageinsertorthelabel

tothephysician.

4.6Adversereactions(frequencyandseriousness)

SomehorseswithheavyinfestationsofOnchocercaspp.microfilariae

haveexperiencedoedemaandpruritisfollowingtreatment;suchreactions

wereassumedtobetheresultofthedeathoflargenumbersof

Revised:October2011

AN:01898/2010

Page4of8

microfilariae.Thesesignsresolvewithinafewdaysbutsymptomatic

treatmentmaybeadvisable.

Incasesofheavyinfestationswithtapeworms,signsofmild,transient

colicandloosestoolmaybeobserved.

Followingadministrationoftheproducttherehavebeenrarereportsof

inflammationofthemouth,lipandtongue,whichresultsinvariousclinical

signssuchasoedema,hypersalivation,erythema,tonguedisorderand

stomatitis..Thesereactionshavebeentransitoryinnature,appearing

within1hourandabatingwithin24to48hoursfollowingadministration.In

caseofsevereoralreactionssymptomatictreatmentisrequired.

4.7Useduringpregnancy,lactationorlay

Studiesperformedinlaboratoryanimalsshowednoteratogenicor

embryotoxiceffectofeitherivermectinorpraziquantelatthe

recommendeddosesduringtherapy.

Ivermectin-Praziquantelcombinationcanbeusedafterthefirstthree

monthsofgestationandduringlactation.Intheabsenceofclinicaldatain

earlypregnancytheproductcanonlybeusedinthefirstthreemonthsof

gestationaccordingtoariskbenefitanalysisbytheveterinarian.

4.8Interactionwithothermedicinalproductsandotherformsof

interaction

Nodataavailable.

4.9Amountstobeadministeredandadministrationroute

Therecommendeddosageis200mcgivermectinperkilogramof

bodyweightand1mgpraziquantelperkilogramofbodyweight

correspondingto1.29gofpasteper100kgbodyweightinasingle

administration.

,Bodyweightanddosageshouldbeaccuratelydeterminedpriorto

treatment.Thecontentsofonesyringewilltreathorsesupto600kg.

Calibratedmarkingsareprovidedat100kgbodyweightintervals.The

syringeshouldbeadjustedtothecalculateddosagebysettingtheringon

theappropriateplaceontheplunger.

Directionsforuse

theproductisfororaladministrationonly.Whileholdingtheplunger,turn

theknurledringontheplunger¼turntotheleftandslideitsothestop

ringisattheprescribedweightmarking.Locktheringinplacebyturningit

¼turntotherightinordertobringthetwoarrows,theonevisibleonthe

ringandtheoneontheplungerrod,intoalignment.Makesurethehorse’s

mouthcontainsnofeed.Removethecoverfromthetipofthesyringe.

Insertthesyringetipintothehorse’smouthattheinterdentalspaceand

depositthepasteonthebaseofthetongue.Immediatelyraisethehorse’s

headforafewsecondsafterdosingandensurethatthepasteis

consumed.

Revised:October2011

AN:01898/2010

Page5of8

ParasitecontrolProgramme

Veterinaryadviceshouldbegivenonappropriatedosingprogramsand

stockmanagementtoachieveadequateparasitecontrolforboth

tapewormandroundworminfestations.

4.10Overdose (symptoms, emergency procedures,antidotes),if

necessary

Noundesirableeffectsrelatedtotreatmentwereobservedin2monthold

horsestreatedwiththeproductatuptothreetimestherecommended

doseandinadulthorsestreatedattentimestherecommendeddose.

Transientdecreasedfoodconsumption,increasedbodytemperature,

salivationandimpairmentofvisionwerenoticedinhorsestreatedtwice

withanivermectinoralpasteoroncewiththeproductattentimesthe

recommendeddose(i.e.,2mg/kgb.w.).Allchangesdisappearedwithin

fivedays.

Noantidotehasbeenidentified;however,symptomatictherapymaybe

beneficial.

4.11Withdrawalperiod(s)

Meat:30days.

Donotuseinmaresproducingmilkforhumanconsumption

5. PHARMACOLOGICALPROPERTIES

Summarypresentationoftheactivesubstance

Pharmacotherapeuticgroup:Anthelmintics

ATCvetcode:QP54AA51ivermectin,combinations.

Theproductisanendectocidecontaininganassociationofan

anthelminticactiveingredient,ivermectin,andacestocideactive

ingredient,praziquantel.

5.1Pharmacodynamicproperties

Ivermectinisamemberofthemacrocycliclactoneclassofendectocides.

Compoundsoftheclassbindselectivelyandwithhighaffinityto

glutamate-gatedchlorideionchannelswhichoccurininvertebratenerve

andmusclecells.Thisleadstoanincreaseinthepermeabilityofthecell

membranetochlorideionswithhyperpolarizationofthenerveormuscle

cell,whichresultsinparalysisanddeathoftheparasite.Compoundsof

thisclassmayalsointeractwithotherligand-gatedchloridechannels,

suchasthosegatedbytheneurotransmittergamma-aminobutyricacid

(GABA).

Revised:October2011

AN:01898/2010

Page6of8

Themarginofsafetyforcompoundsofthisclassisattributabletothefact

thatmammalsdonothaveglutamate-gatedchloridechannels,the

macrocycliclactoneshavealowaffinityforothermammalianligand-gated

chloridechannels,andmacrocycliclactonesdonotreadilycrosstheblood-

brainbarrier.

Praziquantelisasyntheticisoquinoline-pyrazinederivativewithactivity

againstseveraltrematodeandcestodeparasites.Invitroandinvivo

studieshavefoundthattrematodesandcestodesrapidlytakeup

praziquantelwithinminutes;praziquantelcausestetaniccontractionofthe

parasites'musculatureandarapidvacuolisationoftheirtegument.The

neteffectisthattheparasitedetachesfromthehost.Praziquantelaffects

membranepermeabilityintrematodesandcestodes,andinfluences

divalentcationfluxes,particularlycalciumionhomeostasis,whichis

thoughttocontributetotherapidmusclecontractionandvacuolisation.

Themarginofsafetyforthepraziquantelisduetoitsrapidmetabolism

andexcretionaswellasitsselectiveeffectonsusceptibleparasites.

5.2Pharmacokineticparticulars

Afteroraladministrationtohorsesoftherecommendeddoseofthe

product,,praziquantelisrapidlyabsorbedandexcreted,whereas

ivermectinismoreslowlyabsorbedandpersistduringalongerperiodin

thebody.

Praziquantelmaximumplasmaconcentrations(oftheorderof1μg/ml)are

reachedrapidly(approximatelyinthehourfollowingtreatment).The

praziquantelplasmaresiduedepletesrapidlytonon-quantifiablelevelsby

7.5hourspostdose.Praziquantelisexcretedasmetabolitesintheurine

andfaecesandthetotalamountexcretedaccountsfor31%and24%,

respectivelyoftheadministereddosewithin24hours.

Ivermectinmaximumplasmaconcentrations(Cmax:37.9ng/ml)are

reachedinalongerperiod(tmax:approximately9hoursaftertreatment)

andlevelsfelltonondetectable/noquantifiablevaluesonorbefore28

daysafteradministration.

Faecalexcretionisthemajorpathwayofivermectineliminationinall

speciesstudied.

Nopharmacologicalinterferencebetweenivermectinandpraziquantel

werenoted.

Revised:October2011

AN:01898/2010

Page7of8

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

SunsetyellowFCF(E110)

Titaniumdioxide(E171)

Butylhydroxyanisole(E320)

Hydroxypropylcellulose

Hydrogenatedcastoroil

Glycerolformal

6.2Incompatibilities

Notapplicable.

6.3Shelflife

Shelflifeoftheveterinarymedicine:3years.

Shelflifeafterfirstopeningtheimmediatepackaging:2years.

6.4Specialprecautionsforstorage

Storeintheoriginalcontainer.

Replacethecapafteruse.

6.5Natureandcompositionofimmediatepackaging

Immediatepackage

theproductisavailableinsyringescontaining7.74gofpaste:

WhitepolypropylenesyringesbarrelwithawhiteLDPEcap,arubberrod

tipandawhitepolypropyleneplungerrod,withdosedivisionscalibrated

bybodyweight.

Outerpackageandsalespresentations

Cartonboxof1individualsyringe.Eachsyringeissealedinatransparent

polypropylenebag.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

EXTREMELYDANGEROUSFORFISHANDAQUATICLIFE.Donot

contaminatesurfacewatersorditcheswithproductorusedsyringes.Any

unusedproductorwastematerialshouldbedisposedofinaccordancewith

nationalrequirements.

Revised:October2011

AN:01898/2010

Page8of8

7. MARKETINGAUTHORISATIONHOLDER

Janssen-CilagLtd

50-100HolmersFarmWay

HighWycombe

Buckinghamshire

HP124EG

8. MARKETINGAUTHORISATIONNUMBER(S)

Vm 00242/4057

9. DATEOFFIRSTAUTHORISATION

Date:28 th

October2004

10 DATEOFREVISIONOFTHETEXT

Date:October2011

21-11-2018

FDA approves new treatment for patients with acute myeloid leukemia

FDA approves new treatment for patients with acute myeloid leukemia

The FDA approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic health conditions or diseases (comorbidities) that may preclude the use of intensive chemotherapy.

FDA - U.S. Food and Drug Administration

There are no news related to this product.